<DOC>
	<DOCNO>NCT02076659</DOCNO>
	<brief_summary>Phase I , multicenter , open-label , dose escalation study test efficacy safety F8IL10 methotrexate give combination rheumatoid arthritis patient .</brief_summary>
	<brief_title>Combination Therapy F8IL10 Methotrexate Rheumatoid Arthritis Patients</brief_title>
	<detailed_description>The study design explore whether F8IL10 safely administer combination standard-dose MTX patient active rheumatoid arthritis determine recommend dose F8IL10 combine MTX . As soon MTD/RD determine , additional 12 patient randomize ( 6+6 ) F8IL10 ( RD ) placebo investigate safety pharmacacodynamics profile study treatment . Methotrexate ( MTX ) administer concomitant medication dose escalation well randomize part study .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<criteria>Inclusion criterion 1 . Patients age ≥ 18 &lt; 75 year . 2 . Diagnosis RA accord ACR criterion ( 1987 ) disease duration exceed 12 month . 3 . Active RA ( DAS28 ≥ 3.2 ) ≥ 4 month time sign informed consent . 4 . Receiving treatment outpatient basis . 5 . MTX 1015 mg/w period ≥ 8 week prior treatment . 6 . Inadequate clinical response least one antiTNF therapy apply least 4 month . 7 . If patient receive oral corticosteroid , dose must stable least 25 28 day prior study treatment dose must less 10 mg/day ( prednisolone equivalent ) . 8 . All acute toxic effect prior therapy must return classification `` mild '' accord RCTC V.2.0 [ 1 ] . 9 . Sufficient hematologic , liver renal function : Absolute neutrophil count ( ANC ) ≥ 1.5 x 109/L , platelet ≥ 100 x 109/L , hemoglobin ( Hb ) ≥ 9.5 g/dL Alkaline phosphatase ( AP ) , alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) ≤ 3 x upper limit normal range ( ULN ) , total bilirubin ≤ 2.0 mg/dL ( 34.2 µmol/L ) Creatinine ≤ 1.5 ULN 24 h creatinine clearance ≥ 50 mL/min 10 . Documented negative test human immunodeficiency virus , HBV , HCV . For patient serology document previous exposure HBV ( i.e. , antiHBs Ab history vaccination and/or antiHBc Ab ) , negative serum HBV DNA require . 11 . Male female patient , potentially fertile , must agree use adequate contraceptive method begin screen visit must continue 3 month follow last treatment study drug . 12 . Negative serum pregnancy test ( woman childbearing potential ) screening . 13 . Signed dated Ethics Committeeapproved Informed Consent Form indicate patient ( legally acceptable representative ) inform pertinent aspect study . 14 . Willingness ability comply schedule visit , treatment plan , laboratory test study procedure . Exclusion criteria 1 . Presence active infection ( e.g . require antibiotic therapy ) severe concurrent disease , , opinion investigator , would place patient undue risk would interfere study objective conduct . 2 . Pregnancy , lactation unwillingness use adequate contraceptive method . 3 . Active latent tuberculosis ( TB ) . 4 . Chronic active hepatitis active autoimmune disease RA . 5 . History currently active primary secondary immounodeficiency . 6 . HIV Infection . 7 . Acute chronicactive infection HBV HCV , assess serology HBV DNA . 8 . Evidence active malignant disease screen advanced malignancy diagnose within previous 5 year . 9 . Any previous treatment alkylating agent , cyclophosphamide chlorambucil total lymphoid irradiation . 10 . History within last year acute subacute coronary syndrome include myocardial infarction , unstable severe stable angina pectoris . 11 . Treatment warfarin coumarin derivative . 12 . Heart insufficiency ( &gt; Grade II , New York Heart Association ( NYHA ) criterion ) . 13 . Irreversible cardiac arrhythmia require permanent medication . 14 . Clinically significant ( clinical investigator 's discretion ) abnormalities baseline MUGA , ECHO ECG analyse . 15 . Uncontrolled hypertension . 16 . Ischemic peripheral vascular disease ( Grade IIbIV ) . 17 . Severe diabetic retinopathy . 18 . Major trauma include surgery within 4 week administration study treatment . 19 . Known history allergy intolerance IL10 , MTX , folic acid drug base human proteins/peptides/antibodies . 20 . In vivo exposure monoclonal antibody biological therapy ( e.g. , adalimumab , infliximab golimumab , tocilizumab , certolizumab pegol ) less 8 week prior administration study medication . 21 . Treatment rituximab le 4 month prior administration study medication . 22 . Treatment fusion protein ( e.g . abatacept , etanercept ) less 4 week prior administration study medication . 23 . Treatment investigational agent within 6 week study treatment . 24 . Immunization live/attenuated vaccine within 4 week prior baseline . 25 . Growth factor immunomodulatory agent , include anakinra , within 7 day administration study treatment . 26 . Neuropathy &gt; Grade 1 Neuropathies painful condition ( RArelated ) might interfere pain evaluation . 27 . Patients require treated corticosteroid dose &gt; 10 mg/day immunosuppressant drug MTX longterm basis . Limited use corticosteroid treat prevent acute hypersensitivity reaction consider exclusion criterion . 28 . History alcohol , drug chemical substance abuse within 6 month prior screen . 29 . Body weight &gt; 100 kg . 30 . Any condition opinion investigator could hamper compliance study protocol .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>F8</keyword>
	<keyword>IL10</keyword>
	<keyword>Interleukin</keyword>
	<keyword>monoclonal</keyword>
	<keyword>antibody</keyword>
	<keyword>Rheumatoid Arthritis</keyword>
</DOC>